Gland Pharma

GLAND.NS

Hyderabad, India· Est. 1978

glandpharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GLAND.NS · Stock Price

INR 1,870.60+444.60 (+31.18%)

Market Cap: $3.3B

Historical price data

Overview

Gland Pharma's mission is to be a leading global provider of high-quality, affordable injectable medicines. The company has achieved this through a combination of deep expertise in complex sterile manufacturing, strategic partnerships like the one with Fosun Pharma, and a successful IPO in 2020. Its core strategy focuses on expanding its CDMO business, leveraging its R&D for differentiated formulations, and penetrating new regulated and emerging markets to drive sustainable growth.

Anti-infectivesCardiologyCritical CareOncologyNephrologyAnesthesia

Technology Platform

Proprietary expertise in complex sterile injectable manufacturing across multiple delivery systems including vials, pre-filled syringes, lyophilization, and high-potency oncology products, supported by a robust regulatory and quality infrastructure.

FDA Approved Drugs

BRIMONIDINE TARTRATEANDAMar 11, 2026

ZOLEDRONIC ACIDANDAFeb 5, 2026

OLOPATADINE HYDROCHLORIDEANDAJan 6, 2026

Opportunities

The global shift towards outsourcing complex sterile manufacturing (CDMO) and the growing demand for biologics and biosimilars present massive, multi-decade growth opportunities.

Gland's strategic partnership with Fosun uniquely positions it to capture significant market share in the high-growth Chinese pharmaceutical market.

Risk Factors

Key risks include intense pricing pressure in the US generics market, the ever-present threat of regulatory compliance issues at manufacturing facilities, and execution challenges in scaling new, complex capabilities like biologics manufacturing.

Competitive Landscape

Gland Pharma competes with large diversified pharma injectable units (e.g., Pfizer/Hospira) and other Indian pure-play injectable manufacturers. Its competitive advantages are its pure-play focus, scale, cost leadership, and a proven regulatory track record, which are critical in the trust-based CDMO business.